Pediatrix Medical Group (NYSE:MD) Sets New 52-Week High – Should You Buy?

Pediatrix Medical Group, Inc. (NYSE:MD) hit a new 52-week high during trading on Tuesday . The stock traded as high as $24.99 and last traded at $25.0960, with a volume of 132398 shares trading hands. The stock had previously closed at $24.69.

Wall Street Analyst Weigh In

MD has been the subject of several research analyst reports. Mizuho set a $24.00 price target on shares of Pediatrix Medical Group in a research report on Friday, May 8th. UBS Group increased their price objective on Pediatrix Medical Group from $22.00 to $25.00 and gave the stock a “neutral” rating in a report on Tuesday, May 12th. Truist Financial boosted their target price on shares of Pediatrix Medical Group from $21.00 to $23.00 and gave the stock a “hold” rating in a research report on Monday, April 13th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Pediatrix Medical Group in a research report on Wednesday, June 24th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $27.00 target price on shares of Pediatrix Medical Group in a research note on Monday, April 20th. One investment analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, Pediatrix Medical Group currently has a consensus rating of “Hold” and a consensus target price of $22.50.

Pediatrix Medical Group Stock Up 2.3%

The company has a current ratio of 1.33, a quick ratio of 1.33 and a debt-to-equity ratio of 0.45. The company has a market cap of $2.20 billion, a P/E ratio of 12.99 and a beta of 0.66. The firm’s 50 day moving average price is $23.04 and its 200-day moving average price is $21.83.

Pediatrix Medical Group (NYSE:MD) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. The company had revenue of $476.20 million during the quarter, compared to analysts’ expectations of $465.83 million. Pediatrix Medical Group had a return on equity of 19.94% and a net margin of 9.02%.Pediatrix Medical Group’s revenue was up 3.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.33 EPS. As a group, equities research analysts expect that Pediatrix Medical Group, Inc. will post 2.1 EPS for the current year.

Insider Activity at Pediatrix Medical Group

In other Pediatrix Medical Group news, Director Shirley A. Weis sold 36,028 shares of the firm’s stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of $23.75, for a total value of $855,665.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.80% of the company’s stock.

Hedge Funds Weigh In On Pediatrix Medical Group

A number of institutional investors and hedge funds have recently modified their holdings of the company. Global Retirement Partners LLC lifted its position in shares of Pediatrix Medical Group by 68,250.0% in the 4th quarter. Global Retirement Partners LLC now owns 1,367 shares of the company’s stock worth $29,000 after purchasing an additional 1,365 shares during the period. Transamerica Financial Advisors LLC acquired a new stake in Pediatrix Medical Group in the fourth quarter valued at approximately $30,000. Eurizon Capital SGR S.p.A. acquired a new stake in Pediatrix Medical Group in the 4th quarter worth approximately $33,000. Blue Trust Inc. acquired a new stake in shares of Pediatrix Medical Group during the fourth quarter worth $37,000. Finally, TD Private Client Wealth LLC purchased a new position in Pediatrix Medical Group in the 4th quarter worth $39,000. 97.71% of the stock is currently owned by hedge funds and other institutional investors.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.